Clarivate PLC CLVT
We take great care to ensure that the data presented and summarized in this overview for CLARIVATE Plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLVT
View all-
Leonard Green & Partners, L.P. Los Angeles, CA117MShares$661 Million15.78% of portfolio
-
Exor N.V. Amsterdam, P767.3MShares$382 Million100.0% of portfolio
-
Clarkston Capital Partners, LLC Bloomfield Hills, MI57.1MShares$324 Million7.5% of portfolio
-
Impactive Capital LP New York City, NY37.9MShares$215 Million10.64% of portfolio
-
Seth Klarman Baupost Group LLC | Boston, Ma30.6MShares$173 Million6.23% of portfolio
-
Generation Investment Management LLP London, X027MShares$153 Million0.94% of portfolio
-
Glenview Capital Management, LLC New York, NY24.7MShares$140 Million3.22% of portfolio
-
Black Rock Inc. New York, NY22.7MShares$129 Million0.0% of portfolio
-
Fil LTD Hamilton, D019MShares$108 Million0.15% of portfolio
-
Janus Henderson Group PLC London, X012.9MShares$73.1 Million0.05% of portfolio
Latest Institutional Activity in CLVT
Top Purchases
Top Sells
About CLVT
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.
Insider Transactions at CLVT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Julie M Wilson EVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,679
-1.84%
|
$40,074
$6.39 P/Share
|
May 15
2024
|
William E. Graff EVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,261
-2.62%
|
$55,566
$6.39 P/Share
|
May 07
2024
|
Saurabh Saha Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+36.45%
|
-
|
May 07
2024
|
Wendell E. Pritchett Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+32.65%
|
-
|
May 07
2024
|
Richard Roedel Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+20.29%
|
-
|
May 07
2024
|
Valeria Alberola Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+29.14%
|
-
|
May 07
2024
|
Suzanne Heywood Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+50.0%
|
-
|
May 07
2024
|
Andrew Miles Snyder Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+21.96%
|
-
|
May 07
2024
|
Jane L Okun Bomba Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+13.78%
|
-
|
May 07
2024
|
Angelakis Michael J Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,741
+29.74%
|
-
|
May 06
2024
|
Saurabh Saha Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,412
-20.0%
|
$30,884
$7.05 P/Share
|
May 06
2024
|
Wendell E. Pritchett Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,412
-14.88%
|
$30,884
$7.05 P/Share
|
May 06
2024
|
Richard Roedel Director |
SELL
Payment of exercise price or tax liability
|
Direct |
992
-1.41%
|
$6,944
$7.05 P/Share
|
May 06
2024
|
Valeria Alberola Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,647
-7.23%
|
$18,529
$7.05 P/Share
|
May 06
2024
|
Andrew Miles Snyder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,411
-6.78%
|
$30,877
$7.05 P/Share
|
May 06
2024
|
Jane L Okun Bomba Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,745
-1.38%
|
$12,215
$7.05 P/Share
|
May 06
2024
|
Angelakis Michael J Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,206
-6.38%
|
$15,442
$7.05 P/Share
|
May 01
2024
|
Henry Levy President, LS&H |
SELL
Payment of exercise price or tax liability
|
Direct |
39,788
-8.56%
|
$238,728
$6.94 P/Share
|
Mar 31
2024
|
Jane L Okun Bomba Director |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.17%
|
$1,512
$7.43 P/Share
|
Mar 31
2024
|
Jane L Okun Bomba Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,869
+2.96%
|
$27,083
$7.43 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.99M shares |
---|
Payment of exercise price or tax liability | 352K shares |
---|---|
Other acquisition or disposition | 108K shares |